Type I interferons and SARS-CoV-2: from cells to organisms is a research paper published in Current Opinion in Immunology (2022). On theSindex it has a DataRank of 0.665. It has been cited 83 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.665
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NCATS NIH HHS
Grant: UL1 TR001866
NHGRI NIH HHS
Grant: UM1 HG006504
NIH HHS
Grant: S10 OD018521
NIAID NIH HHS
Grant: R01 AI088364
NIAID NIH HHS
Grant: R01 AI163029
NHGRI NIH HHS
Grant: U24 HG008956
FWCI
7.62
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Additional file 1 of LINC01002 functions as a ceRNA to regulate FRMD8 by sponging miR-4324 for the development of COVID-19
Additional file 1 of LINC01002 functions as a ceRNA to regulate FRMD8 by sponging miR-4324 for the development of COVID-19
Additional file 2 of LINC01002 functions as a ceRNA to regulate FRMD8 by sponging miR-4324 for the development of COVID-19
Additional file 2 of LINC01002 functions as a ceRNA to regulate FRMD8 by sponging miR-4324 for the development of COVID-19
Additional file 1 of Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study
Additional file 1 of Auto-antibodies against type I IFNs in > 10% of critically ill COVID-19 patients: a prospective multicentre study